EN DE
STOCK COMPARISON

Septerna, Inc. Common Stock vs Vertex Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Septerna, Inc. Common Stock (SEPN) and Vertex Pharmaceuticals (VRTX) compare, as of Aug 10, 2026.

As of Aug 10, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Septerna, Inc. Common Stock trades at $38.83 versus a fair value of $4.43 (-89%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).
Septerna, Inc. Common Stock
SEPN · USD · Health Care
-89%
upside to fair value
overvalued
Price$38.83
Fair Value$4.43
Quality50/100
Vertex Pharmaceuticals
VRTX · USD · Health Care
-44%
upside to fair value
overvalued
Price$496
Fair Value$279
Quality79/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Septerna, Inc. Common StockVertex Pharmaceuticals
Valuation
—P/E (TTM)28.8×
21.74×P/S (TTM)10.06×
4.11×P/B6.59×
—EV/EBITDA23.8×
—PEG1.72×
Profitability
-50%Net margin36%
-50%Operating margin38%
-9%Return on equity24%
-8%Return on assets12%
Growth
12011%Revenue growth (YoY)8%
—Avg. growth/yr (3Y)10.6%
—Avg. growth/yr (5Y)14.2%
Balance & size
—Debt / equity0.03×
$2BMarket cap$123B
mixedGrowth qualityhealthy

Vertex Pharmaceuticals leads: 2 to 5 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Septerna, Inc. Common Stockof which business quality 57 · market factors 70 Vertex Pharmaceuticalsof which business quality 77 · market factors 65
ProfitabilityMargins and returns on capital today
3
72
Quality GrowthAre margins and returns improving?
88
65
CashflowEarnings quality: real cash, not paper profit
100
79
Fin. StrengthBalance sheet, leverage, solvency risk
92
92
InvestmentDisciplined investing over empire-building
50
58
Low VolatilityCalm price path (market factor)
0
86
MomentumPrice trend over the last 3–12 months (market factor)
100
54
52W MomentumDistance to the 52-week high (market factor)
100
59
Net IssuanceBuybacks instead of dilution
0
82

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Septerna, Inc. Common Stock

DCF Models$32.54
Multiples$5.74
Asset-Based$5.68
Growth DCF$56.30

4 of 6 models see the stock below the current price.

Vertex Pharmaceuticals

DCF Models$453
Earnings-Based$516
Dividend Discount$7.07
Multiples$278
Asset-Based$49.27
Growth DCF$348
Economic Profit$254
Growth Earnings$692

18 of 26 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Septerna, Inc. Common Stock
Bear $3.65Fair Value $4.43Bull $5.21
$38.83 = current price (white tick)
Vertex Pharmaceuticals
Bear $210Fair Value $279Bull $900
$496 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Septerna, Inc. Common Stock · Health Care

Quality score50 · below median
Fair value upside-89% · bottom 25%

Vertex Pharmaceuticals · Health Care

Quality score79 · Top 25%
Fair value upside-44% · below median

Bottom line

As of Aug 10, 2026, Fair Value Calculator sees Vertex Pharmaceuticals as the less overvalued of the two: Septerna, Inc. Common Stock trades at $38.83 versus a fair value of $4.43 (-89%), while Vertex Pharmaceuticals trades at $496 versus $279 (-44%).

Vertex Pharmaceuticals has the higher quality score (79/100).

See the full analysis →
Septerna, Inc. Common Stock · Vertex Pharmaceuticals

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Related to Septerna, Inc. Common Stock

Eli Lilly and vs UnitedHealth GroupJohnson & Johnson vs UnitedHealth GroupAbbVie vs UnitedHealth GroupUnitedHealth Group vs Merck & Company

Related to Vertex Pharmaceuticals

UnitedHealth Group vs AstraZenecaUnitedHealth Group vs Thermo Fisher ScientificUnitedHealth Group vs AmgenUnitedHealth Group vs Abbott Laboratories
Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.